ALLAKOS INC. - COMMON STOCK

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

02 апр 2025 08:00:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

12 мар 2025 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

27 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

10 окт 2024 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

07 авг 2024 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

25 июн 2024 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

28 май 2024 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

09 май 2024 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 мар 2024 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

26 фев 2024 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

12 фев 2024 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces a Restructuring to Focus on Development of AK006

16 янв 2024 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

16 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

13 ноя 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Appoints Neil Graham to its Board of Directors

30 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

09 авг 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

02 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

12 июн 2023 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

05 июн 2023 07:02:00 Источник Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

09 май 2023 16:02:00 Источник Nasdaq GlobeNewswire